Cytosorbents Corp (CTSO)
NASDAQ:CTSO
Want to see CTSO full AI Analyst Report?
CTSO Stock Chart & Stats
$0.70
-$0.05(-4.55%)
At close: 4:00 PM EST
$0.70
-$0.05(-4.55%)
Day’s Range― - ―
52-Week Range$0.37 - $1.39
Previous CloseN/A
Volume86.19K
Average Volume (3M)134.35K
Market Cap
$25.95M
Enterprise Value$44.10M
Total Cash (Recent Filing)$4.81M
Total Debt (Recent Filing)$18.96M
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Aug 04, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding62,842,747
10 Day Avg. Volume163,660
30 Day Avg. Volume134,354
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)6.74
Price to Sales (P/S)1.07
P/FCF Ratio-3.17
Enterprise Value/Market Cap1.70
Enterprise Value/Revenue1.19
Enterprise Value/Gross Profit1.67
Enterprise Value/Ebitda-5.67
Forecast
1Y Price Target
$0.75Price Target Upside7.14% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-0.16
Revenue Forecast (FY)$39.28M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained gross margins near 70% indicate strong product-level economics and pricing power for the disposable cartridge model. High unit profitability supports reinvestment in commercial expansion and clinical work, helping the company move toward durable operating leverage and breakeven.
Large Installed Base & Recurring ModelA global installed base of 300k+ treatments supports recurring 'razor/razor-blade' consumable demand, giving predictable recurring revenue per procedure. This structural adoption across many hospitals underpins scalable sales and durable customer relationships as hospital procedure volumes grow.
Clinical Evidence & Regulatory EngagementPositive randomized trial results and Breakthrough Device designations materially de‑risk clinical adoption and regulatory pathways. Robust clinical evidence supports guideline uptake and hospital purchasing decisions, increasing the long‑term addressable market and easing commercialization once approvals proceed.
Bears Say
High Leverage & Compressed EquityVery high leverage and a compressed equity base sharply reduce financial flexibility and raise refinancing or dilution risk. This structural balance‑sheet weakness constrains the company’s ability to self‑fund trials, regulatory activities, or commercial scale without external capital or dilutive financings.
Persistent Cash Burn And Limited LiquidityOngoing negative operating and free cash flow alongside a small cash balance create a short runway for funding operations and required regulatory studies. Structural cash burn increases dependence on external financing, which can delay projects, restrict commercialization or force dilution when markets are unfavorable.
FDA De Novo Delay And Additional Study NeedsAdditional mechanistic study requirements and a delayed de novo submission push U.S. market access further out, deferring TAM monetization and increasing resource needs. Structurally, this lengthens the commercialization timeline and raises the likelihood of needing extra capital to support required studies.
Cytosorbents News
CTSO FAQ
What was Cytosorbents Corp’s price range in the past 12 months?
Cytosorbents Corp lowest stock price was $0.37 and its highest was $1.39 in the past 12 months.
What is Cytosorbents Corp’s market cap?
Cytosorbents Corp’s market cap is $25.95M.
When is Cytosorbents Corp’s upcoming earnings report date?
Cytosorbents Corp’s upcoming earnings report date is Aug 04, 2026 which is in 42 days.
How were Cytosorbents Corp’s earnings last quarter?
Cytosorbents Corp released its earnings results on May 13, 2026. The company reported -$0.08 earnings per share for the quarter, missing the consensus estimate of -$0.05 by -$0.03.
Is Cytosorbents Corp overvalued?
According to Wall Street analysts Cytosorbents Corp’s price is currently Undervalued.
Does Cytosorbents Corp pay dividends?
Cytosorbents Corp does not currently pay dividends.
What is Cytosorbents Corp’s EPS estimate?
Cytosorbents Corp’s EPS estimate is -0.04.
How many shares outstanding does Cytosorbents Corp have?
Cytosorbents Corp has 62,842,747 shares outstanding.
What happened to Cytosorbents Corp’s price movement after its last earnings report?
Cytosorbents Corp reported an EPS of -$0.08 in its last earnings report, missing expectations of -$0.05. Following the earnings report the stock price went down -5.088%.
Which hedge fund is a major shareholder of Cytosorbents Corp?
Currently, no hedge funds are holding shares in CTSO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cytosorbents Corp
Cytosorbents Corporation specializes in creating and bringing to market innovative medical devices. Their core expertise lies in a unique blood purification platform, built upon a proprietary adsorbent and porous polymer technology. The company's leading product, CytoSorb, is an extracorporeal filter designed to remove cytokines from the blood. It serves as a complementary treatment in various critical care scenarios, including sepsis, managing complications during and after heart bypass surgery, and improving the viability of donor organs for transplantation. Beyond CytoSorb, Cytosorbents offers a portfolio of specialized devices. These include VetResQ, used to assist in treating critical conditions like sepsis and pancreatitis in animals; CytoSorb-XL, another device targeting sepsis and other severe illnesses; HemoDefend, a platform for purifying blood supplies by removing contaminants that cause transfusion reactions and diseases, as well as anti-A and anti-B antibodies from blood products; K+ontrol, designed for patients with severe, life-threatening hyperkalemia; and ContrastSorb, which extracts intravenous contrast agents following imaging procedures (like CT scans, angiograms, or interventional radiology) to mitigate the risk of contrast-induced kidney damage. The company is also actively developing several new solutions: BetaSorb, aimed at preventing and treating complications from metabolic toxin buildup in chronic kidney disease patients; DrugSorb, which focuses on eliminating harmful chemicals from the bloodstream; and DrugSorb-ATR, an innovative system for removing antithrombotic agents. Originally established as MedaSorb Technologies Corporation in 1997, the company adopted its current name, Cytosorbents Corporation, in May 2010. Its corporate headquarters are situated in Princeton, New Jersey.
CTSO Company Deck
CTSO Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call balanced operational and commercial progress against near‑term financial and regulatory challenges. Positives include modest top-line growth, strong international direct momentum (+13% YoY), healthy gross margins (69%), improved adjusted profitability metrics, strengthening clinical evidence (STAR-T showing >50% reduction in severe bleeding), and clearer regulatory direction with two FDA breakthrough designations. Main negatives are the widened GAAP net loss driven by FX, lower cash balance (~$6.4M), a delayed de novo submission requiring additional mechanistic studies and resources (likely pushing approval into late 2026/early 2027), Germany market softness, and a $0.5M order disruption tied to geopolitical events. Overall, management is executing cost reductions and targeting operating cash flow breakeven in H2 2026, and the call conveyed cautious optimism despite the identified risks.View all CTSO earnings summariesCTSO Stock 12 Month Forecast
Average Price Target
$0.75
▲(7.14% Upside)
Technical Analysis
Electrocore
―
TELA Bio
―
Spectral AI
―
Icecure Medical
―
Baird Medical Investment Holdings
―
Ownership Overview
6.50% Insiders
6.65% Mutual Funds
14.72% Other Institutional Investors
68.92% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---